Assenagon Asset Management S.A. Acquires New Position in Omnicell, Inc. (NASDAQ:OMCL)

Assenagon Asset Management S.A. purchased a new position in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 363,739 shares of the company's stock, valued at approximately $13,687,000. Assenagon Asset Management S.A. owned 0.80% of Omnicell at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its holdings in shares of Omnicell by 15.1% in the third quarter. Vanguard Group Inc. now owns 5,137,084 shares of the company's stock valued at $231,374,000 after purchasing an additional 674,824 shares during the last quarter. Macquarie Group Ltd. raised its holdings in shares of Omnicell by 12.5% during the 2nd quarter. Macquarie Group Ltd. now owns 1,218,279 shares of the company's stock worth $138,579,000 after acquiring an additional 135,360 shares during the period. Clearbridge Investments LLC boosted its position in shares of Omnicell by 8.9% during the 1st quarter. Clearbridge Investments LLC now owns 1,136,664 shares of the company's stock valued at $147,187,000 after acquiring an additional 92,567 shares during the last quarter. Pacer Advisors Inc. grew its holdings in shares of Omnicell by 321,488.8% in the fourth quarter. Pacer Advisors Inc. now owns 1,058,027 shares of the company's stock valued at $39,814,000 after purchasing an additional 1,057,698 shares during the period. Finally, Geode Capital Management LLC increased its position in Omnicell by 5.9% during the second quarter. Geode Capital Management LLC now owns 933,000 shares of the company's stock worth $68,734,000 after purchasing an additional 52,030 shares during the last quarter. 97.70% of the stock is currently owned by institutional investors.

Omnicell Trading Down 0.0 %

NASDAQ:OMCL traded down $0.01 during trading hours on Friday, reaching $29.23. 447,440 shares of the stock were exchanged, compared to its average volume of 562,563. Omnicell, Inc. has a twelve month low of $25.69 and a twelve month high of $77.14. The company has a quick ratio of 2.22, a current ratio of 2.52 and a debt-to-equity ratio of 0.48. The business has a 50-day moving average of $29.23 and a two-hundred day moving average of $35.27. The company has a market capitalization of $1.34 billion, a price-to-earnings ratio of -64.96 and a beta of 0.74.

Omnicell (NASDAQ:OMCL - Get Free Report) last posted its earnings results on Thursday, February 8th. The company reported $0.12 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.22. The firm had revenue of $258.85 million for the quarter, compared to analyst estimates of $256.00 million. Omnicell had a positive return on equity of 3.43% and a negative net margin of 1.78%. On average, equities analysts predict that Omnicell, Inc. will post 0.1 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have weighed in on the stock. Benchmark dropped their price target on shares of Omnicell from $42.00 to $38.00 and set a "buy" rating for the company in a research note on Friday, February 9th. Wells Fargo & Company lowered their price objective on Omnicell from $28.00 to $26.00 and set an "equal weight" rating for the company in a research report on Friday, February 9th. Finally, Barclays assumed coverage on Omnicell in a research report on Wednesday, January 3rd. They issued an "underweight" rating and a $33.00 target price on the stock. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Hold" and an average price target of $42.20.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.